Fecal Calprotectin and Quality of Life Questionnaires Are Responsive to Change in Pouch Disease Activity After Antibiotic Therapy: Results From a Prospective Clinical Trial

Am J Gastroenterol. 2023 Feb 1;118(2):367-370. doi: 10.14309/ajg.0000000000002038. Epub 2022 Sep 30.

Abstract

Introduction: Whether fecal calprotectin (FC) and quality of life (QoL) questionnaires reflect change in disease activity in patients with a J-pouch is unknown.

Methods: Patients with acute pouchitis were prospectively treated with a 2-week course of antibiotics. The full Pouchitis Disease Activity Index, FC, and QoL questionnaires were measured at baseline and after antibiotic therapy.

Results: Twenty patients were prospectively enrolled. After 2 weeks of antibiotic treatment, the Pouchitis Disease Activity Index decreased from a median of 9 to 5 ( P = 0.007). FC decreased from a median of 661 ug/g to 294 ug/g ( P = 0.02), and QoL questionnaires improved significantly.

Discussion: FC and QoL questionnaires reflect real-time changes in inflammatory pouch activity.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Colitis, Ulcerative* / drug therapy
  • Feces
  • Humans
  • Leukocyte L1 Antigen Complex
  • Pouchitis* / drug therapy
  • Prospective Studies
  • Quality of Life

Substances

  • Leukocyte L1 Antigen Complex
  • Anti-Bacterial Agents